Ankita Mitra
Providence Portland Medical Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Massachusetts Amherst, University of Calcutta, NYU Langone Health Perlmutter Cancer Center
Research areas: Immunology and Microbiology · Immunology · T-cell and B-cell Immunology · Cancer Immunotherapy and Biomarkers · Adenosine and Purinergic Signaling
0000-0002-7368-1965
About
Immunologist with interest in Immuno-Oncology, T cell biology, and signaling. As a graduate research assistant, I have done extensive studies on Notch signaling pathway and its influence on the biology and function of CD4 T cells. I have used mouse models and immunomodulatory drugs to understand the crosstalk between Notch signaling and other T-cell signaling pathways. I have also worked on phenotyping human mammoplasty samples to understand the impact of parity-associated immunosurveillance on the development of breast cancer.
As a postdoctoral fellow, I am working on identifying biomarkers and their underlying mechanisms of action in developing resistance towards Immune checkpoint blockade in an advanced melanoma patients. I am also studying different artificial antigen-presenting cell (aAPC) platforms in comparison to autologous DCs in expanding tumor-associated antigen or NeoAntigen-specific CD8 T cells for adoptive transfer, from melanoma patient PBMCs. This involves functional analysis and extensive phenotyping of the expanded cells to understand the efficacy of the platforms in comparison to the autologous DCs.
I have extensive experience in multicolor flow cytometry with complex panels (including spectral), human and murine T cell culture, T cell functional assays, multiplex bead-based cytokine, and single-cell secretome assays, expressing proteins in mammalian cells and purification. administering cells and compounds in mice (IV, oral gavaging).
Employment
-
Providence Portland Medical Center Research Scientist
-
NYU Langone’s Laura and Isaac Perlmutter Cancer Center Research Consultant
-
NYU Langone Health Perlmutter Cancer Center Postdoctoral fellow
Education
- 2013 - 2019
-
University of Calcutta Master of Science2011 - 2013
-
Lady Brabourne College Bachelor of Science2008 - 2011
Projects & Funding
Projects & funding information is unavailable.
Publications (33)
- CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- Supplementary Figures 1-7 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- Supplementary Tables 1-8 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Data from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Supplementary Figures 1-7 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Supplementary Figures 1-7 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Supplementary Tables 1-8 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Supplementary Tables 1-8 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance Save
- Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion Save
- A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save
- CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Save